Robust Single-Dose rAAV Dual-Targeting PCSK9/APOC3 via an Optimized Triple-Plasmid System for Ameliorating Mixed Hyperlipidemia
Year: 2026
Type: preprint
Abstract: Mixed hyperlipidemia is characterized by concurrent hypercholesterolemic and hypertriglyceridemic burdens, which cannot be adequately addressed by existing single-target lipid-lowering strategies, leaving patients with considerable residual cardiovascular risk. Herein, we developed a single dual-target rAAV carrying a dual-promoter cassette simultaneously silences PCSK9 and APOC3, and established an optimized triple-plasmid packaging strategy to overcome the bottleneck imposed by its large (~ 5.3 kb) cargo. Systematic titration of the three packaging plasmids identified a three-fold increase in pHelper dosage as the optimal balance of replication and packaging resources, which elevated viral yield, restored the canonical 1:1:10 capsid stoichiometry, and markedly reduced the empty-capsid fraction.In a high-fat-diet mouse model, a single administration of this dual-target rAAV concurrently knocked down hepatic PCSK9 and APOC3, reducing serum TC by approximately 30% and TG by approximately 70%, with an approximately 40% gain in editing efficiency over the unoptimized vector. Moreover, this optimized dual-target rAAV offered superior advantages over single-target AAV in ameliorating systemic energy metabolic phenotypes, manifested as increased energy expenditure and a reduced respiratory exchange ratio. Overall, this study provides a feasible strategy for producing large-cargo dual-target rAAVs and establishes proof-of-concept for single-administration, dual-target gene therapy against mixed hyperlipidemia.
Source: Research Square
Language: English
Subfield: Genetics
Domain: Life Sciences
Open Access status: green
OpenAlex ID: W7236062250
